INTRODUÇÃO: O câncer colorretal metastático (CCRm) é uma doença clinicamente e molecularmente heterogênea. Os pacientes apresentam diferentes prognósticos e respostas variáveis às terapias direcionadas contra o tumor. Alterações na função do sistema de reparo do DNA (deficiency mismatch repair - dMMR) estão associadas com o fenótipo de instabilidade de microssatélites e bom prognóstico em tumores de estádio inicial. No entanto, dMMR é raro no CCRm e pouco se sabe sobre sua influência na taxa de resposta (TR) ao tratamento. Nosso objetivo primário foi comparar a TR, de acordo com o status dMMR, nos pacientes com CCRm. Os desfechos secundários foram TR, conforme RAS e BRAF mutados, e a sobrevida global (SG), de acordo com dMMR. MÉTODOS: Estudo retrospectivo com grupo controle que comparou a TR por RECIST 1.1 em pacientes com CCRm, tratados com quimioterapia (QT) sistêmica, de acordo com o status dMMR. Os dados clínicos foram coletados, retrospectivamente, dos prontuários médicos. Todas as imagens foram digitais e recuperadas para avaliação de resposta por um único radiologista, cego quanto ao status dMMR. dMMR foi definido como a perda de expressão imuno-histoquímica em pelo menos um dos genes MMR (MLH1, MSH2, MSH6 e PMS2). Mutações em RAS e BRAF foram investigadas por meio de sequenciamento gênico. Os casos foram os pacientes com dMMR, e os controles, com MMR proficiente (pMMR), selecionados de forma consecutiva, em proporção de 1:2. Com base em características clínicas e moleculares, os indivíduos dMMR foram classificados como provável Lynch ou dMMR esporádico. Estatística descritiva foi usada para resumir os resultados. A associação entre dMMR e os resultados específicos de cada grupo foram analisados pelo teste do qui-quadrado, e para a avaliação de SG mediana, curvas de Kaplan-Meier e teste log-rank foram utilizados. Valores bicaudados de p < 0.05 foram considerados significativos. RESULTADOS: Entre janeiro de 2009 e janeiro de 2013, de 1270 pacientes, 762 foram elegíveis e rastreados para dMMR: N = 27 (3,5%) tiveram dMMR e N = 735 (96,5%) tiveram pMMR. Dada a raridade, foram incluídos 14 indivíduos com dMMR fora do período de inclusão, totalizando 41 casos (pacientes dMMR) e 84 controles (pacientes pMMR). Em análise por intenção de tratamento, considerando os pacientes que receberam pelo menos uma dose de QT baseada em oxaliplatina (N dMMR = 34), aqueles com dMMR apresentaram TR numericamente menor, comparados aos pMMR (11.7% vs 28.6%, OR: 0.33, IC 95%: 0.08-1.40, p = 0.088). Em análise por protocolo, incluindo apenas os pacientes que preencheram os critérios de inclusão (N dMMR = 33), aqueles com dMMR mantiveram TR menor à QT baseada em oxaliplatina em primeira linha, em comparação aos doentes pMMR, embora estatisticamente não significante (12.1% vs 28.6 %, OR: 0.34, IC 95%: 0.09-1.18, p = 0.102). Ainda neste contexto, os pacientes com possível Lynch apresentaram maior TR do que os indivíduos com provável dMMR esporádico (16% vs 0). Mutações em RAS ou BRAF não influenciaram na TR ou sobrevida. O status \"provável dMMR esporádico\" foi fator de pior prognóstico, quando todos os pacientes da amostra (N dMMR = 41) foram considerados. CONCLUSÃO: Este estudo sugere que dMMR é preditivo de resistência à quimioterapia baseada em oxaliplatina, como mostrado por outros estudos. Aparentemente, essa resistência é mais acentuada nos pacientes dMMR esporádicos, sugerindo heterogeneidade biológica nos doentes com CCRm e dMMR / BACKGROUND: Metastatic colorectal cancer (mCRC) is a clinically and molecularly heterogeneous disease, where patients present different prognosis and variable responses to cancer-directed therapies. Alterations in the function of DNA deficiency mismatch repair (dMMR) genes are associated with microsatellite instability and good prognosis in early stage tumors. However dMMR dysfunction is rare in mCRC and little is known about its influence on treatment response rate (RR). Our primary endpoint was to compare the RR of mCRC patients according to dMMR status and to explore differences between patients with likely sporadic versus likely Lynch-related tumors. Secondary endpoints were RR according to RAS and BRAF mutation status, and survival times as per dMMR status. METHODS: Retrospective study with control group that compared the RR by RECIST 1.1 in patients with mCRC treated with systemic chemotherapy according to dMMR status. Clinical data were collected retrospectively from medical charts. All images were digital and were retrieved for response evaluation by a single radiologist blinded to dMMR results. dMMR status was defined as loss of immunohistochemistry expression in at least one of the MMR genes (MLH1, MSH2, MSH6 e PMS2). RAS and BRAF mutations were investigated through next generation sequencing. Cases were defined as dMMR and controls, as proficient MMR (pMMR) patients, in a 1:2 fashion. Based on clinical and molecular features, dMMR patients were classified as likely Lynch or sporadic. Descriptive statistics was used to summarize the results. The association between dMMR and outcomes of each group were analyzed by chi-square test; estimates of median overall survival were done by the Kaplan-Meier method and comparisons, by the log-rank test. Two-tailed p values < 0.05 were considered significant. RESULTS: From January 2009 to January 2013, out of 1270 patients, 762 were eligible and screened for dMMR: N = 27 (3.5%) had dMMR and N = 735 (96.5%) had pMMR. Given the rarity, 14 dMMR cases outside the inclusion period were included, with a total of 41 cases (dMMR patients) and 84 controls (pMMR patients). By intention-to-treat analysis, considering all patients who received at least one dose of oxaliplatin-based chemotherapy (N dMMR = 34), those with dMMR had numerically lower RR, compared with pMMR (RR = 11.7% vs 28.6%, OR: 0.33, 95% CI: 0.08-1.40, p = 0.088). As per protocol analysis, considering only the patients who met inclusion criteria (N dMMR = 33), those with dMMR status persisted with numerically, but non-significant, lower RR to first-line oxaliplatin-based chemotherapy compared with pMMR (12.1% vs 28.6%, OR: 0.34, 95% CI: 0.09-1.18, p = 0.102); also, patients with likely Lynch-related mCRC presented higher RR than subjects with probable sporadic dMMR (16% vs 0). Either survival or RR was influenced by RAS or BRAF mutations. Probable sporadic dMMR status was a poor prognostic factor when all patients in the sample (N dMMR = 41) were analyzed. CONCLUSION: This study suggests that the dMMR phenotype is predictive of resistance to oxaliplatin-based chemotherapy, as shown by other studies. Apparently, such resistance is more pronounced in the sporadic dMMR patients, suggesting biological heterogeinity within the dMMR mCRC patients

INTRODUÇÃO: As fraturas do terço médio da clavícula representam 80% das fraturas claviculares e seu tratamento é motivo de discussão na literatura ortopédica. Estudos prévios relativos ao tratamento cirúrgico têm demonstrado bons resultados clínicos com o uso das placas de reconstrução ou a fixação intramedular elástica estável com hastes flexíveis de titânio. O objetivo deste estudo foi a comparação desses métodos no tratamento das fraturas do terço médio da clavícula, quanto aos resultados funcionais, parâmetros radiográficos, dor pós-operatória, taxa de satisfação e taxa de complicações. MÉTODOS: Neste ensaio clínico comparativo, prospectivo e randomizado, 59 pacientes com fratura desviada do terço médio da clavícula foram alocados aleatoriamente para receberem osteossíntese com placa de reconstrução (33 pacientes - grupo Placa) ou haste flexível de titânio (26 pacientes - grupo Haste). O desfecho primário do estudo foi a avaliação funcional pelo escore DASH aos 6 meses de pós-operatório. Os desfechos secundários foram: o escore DASH aos 12 meses; o escore de Constant- Murley aos 6 e 12 meses; o tempo de consolidação da fratura; o encurtamento residual; o nível de dor pela escala visual analógica no 1º pósoperatório; a taxa de pacientes satisfeitos e a taxa de complicações. RESULTADOS: Cinquenta e quatro pacientes completaram o seguimento, sendo 29 do grupo Placa e 25 do grupo Haste. O escore DASH médio aos 6 meses foi de 9,9 pontos no grupo Placa e 8,5 no grupo Haste, sem diferença estatisticamente significante (p = 0,329). Da mesma forma, não houve diferenças significantes no escore DASH aos 12 meses ou no escore de Constant aos 6 e 12 meses. O tempo de consolidação foi equivalente entre os grupos (p = 0,352), enquanto o encurtamento residual foi maior no grupo Placa, com significância estatística (p = 0,032), mas sem relevância clínica (0,4 cm). Os resultados da escala visual analógica para dor no 1º pósoperatório e a taxa de pacientes satisfeitos foram similares entre os grupos. O grupo Placa apresentou mais casos com angulação do implante (11 casos) do que o grupo Haste (um caso) (p = 0,003), enquanto o grupo Haste foi mais associado à dor relacionada ao implante (10 casos), em comparação ao grupo Placa (4 casos) (p = 0,035). Não houve diferenças significantes entre os grupos quanto às complicações maiores, incluindo falha do implante, infecção pós-operatória, pseudoartrose e reoperação. CONCLUSÕES: A osteossíntese das fraturas desviadas do terço médio da clavícula com placa de reconstrução ou haste flexível de titânio produzem resultados semelhantes quanto aos escores funcionais, tempo de consolidação, dor pós-operatória, satisfação dos pacientes e complicações maiores. As placas de reconstrução são mais suscetíveis à angulação do implante, enquanto as hastes flexíveis de titânio causam mais dor relacionada ao implante / INTRODUCTION: Midshaft clavicle fractures represent 80% of all clavicular fractures, and their treatment is controversial in the literature. Previous studies have shown good clinical results in patients with midshaft clavicular fractures treated with reconstruction plate fixation or elastic stable intramedullary nailing (ESIN). The objective of this study was to compare these methods in terms of functional results, radiographic parameters, postoperative pain, satisfaction rates and complication rates. METHODS: In this prospective, randomized, controlled trial, 59 patients with displaced midshaft clavicular fractures were randomly assigned to receive either reconstruction plate (33 patients - Plate group) or ESIN fixation (26 patients - ESIN group). The primary outcome was the DASH score at 6 months. The secondary outcomes were the following: DASH score at 12 months; Constant-Murley scores at 6 and 12 months; time to fracture union; residual shortening; visual analog scale for pain on the first post-operative day; percentage of satisfied patients; and complications rates. RESULTS: Fifty-four patients completed the follow-up, 29 in the Plante group and 25 in the ESIN group. The mean DASH score at 6 months was 9.9 in the plate group and 8.5 in the ESIN group, with no significant difference (p = 0.329). Similarly, there were no differences in the DASH score at 12 months or the Constant-Murley scores at 6 and 12 months. The time to union was equivalent between the groups (p = 0.352), whereas the residual shortening was significantly greater in the plate group (p = 0.032) but was not clinically relevant (0.4 cm). The visual analog scale scores for pain and the percentage of satisfied patients were similar between the groups. Implant bending was significantly more common in the plate group (eleven patients) than in the ESIN group (one patient) (p = 0.003), whereas hardware-related pain was more frequent in the ESIN group (10 patients vs. 4 patients) (p = 0.035). There were no differences in terms of major complications, including implant failure, postoperative infection, nonunion and reoperation. CONCLUSIONS: Reconstruction plates and ESIN yielded similar results in terms of functional results, time to union, post-operative pain, patient satisfaction and major complications in patients with displaced midshaft clavicular fractures. Reconstruction plates are more susceptible to implant bending, whereas ESIN causes more hardwarerelated pain

INTRODUÇÃO: O polivinilpirrolidona-iodo (PVP-I) tópico vem sendo descrito como um agente esclerosante para pleurodese de fácil obtenção, baixo custo e com boa eficácia. Apesar disso, sua segurança ainda não foi estudada de maneira sistemática e alguns autores apresentam restrições ao seu uso por relatos de determinados eventos adversos. OBJETIVOS: descrever a ocorrência de eventos adversos sérios e comuns à pleurodese com PVP-I tópico. Avaliar se existe relação de dose-dependência na ocorrência dos eventos adversos; a efetividade clínica e a qualidade de vida dos pacientes. MÉTODOS: ensaio clínico envolvendo pacientes submetidos a pleurodese com PVP-I tópico, randomizados em dois grupos: grupo 1 com PVP-I tópico a 1% e grupo 2 com PVP-I tópico a 2%. A análise de segurança foi baseada na ocorrência de eventos adversos, graduados de acordo com o Common Terminology Criteria for Adverse Events. Foram realizadas avaliações clínicas e exames complementares no pré-operatório e em vários momentos do seguimento pós-operatório. Os dados clínicos avaliados foram dor, dispnéia, temperatura, pressão arterial, freqüência cardíaca, saturação de oxigênio e acuidade visual. Exames complementares envolveram hemograma, função renal, hepática e tireoidiana, eletrocardiograma e radiografia de tórax. A efetividade clínica foi determinada pela necessidade de procedimentos adicionais após a pleurodese e a qualidade de vida através de questionário específico. RESULTADOS: foram avaliados 60 pacientes, 30 em cada grupo. Predominou o sexo feminino, em 55 pacientes. A média de idade foi de 55,9 ± 11,7 anos. A etiologia mais comum do derrame pleural foi neoplasia de mama em 43 pacientes, seguida por neoplasia pulmonar e de ovário. Foram encontrados 47 eventos adversos sérios relacionados ao procedimento distribuídos em 34 pacientes nos primeiros 30 dias de avaliação. Foram eles: dor, em onze pacientes, hipertensão em dez, empiema em um, hiponatremia em oito pacientes, elevação da fosfatase alcalina, transaminase oxalacética e transaminase pirúvica em dez, três e um pacientes respectivamente e hipocalemia em um paciente. A taxa de sucesso foi de 96% e não houve mudança na qualidade de vida após o procedimento. Na comparação dos grupos não se observou diferença estatística em relação aos dados avaliados. CONCLUSÕES: Os eventos adversos sérios mais esperados após a realização de pleurodese com PVP-I tópico são dor, hipertensão e alguns distúrbios metabólicos. A pleurodese com PVP-I tópico mostrou ser um procedimento eficaz, mas não ofereceu melhora na qualidade de vida dos pacientes. Não se observou relação de dose-dependência na ocorrência dos eventos adversos e na eficácia do procedimento / BACKGROUND: Iodopovidone has been described as a sclerosing agent easily obtained, inexpensive and with good results. Despite this, its safety has not been systematically evaluated and some authors have restrictions to its use because of reports of some adverse events related. OBJECTIVE: To describe the occurrence of common and serious adverse events after iodopovidone pleurodesis. Second endpoints were to describe dose-dependent relation to adverse events, procedure efficacy and patient\'s quality of life. METHODS: clinical trial including patients with recurrent malignant pleural effusion, undergone to pleurodesis, randomized into two groups: group 1 received 1% iodopovidone and group 2 received 2% Iodopovidone. We sought adverse events systematically with clinical and complementary evaluations since before pleurodesis and on several times postoperative. Clinical evaluation involved pain analog scale, dyspnea scale, oxygen saturation, heart frequency, arterial blood pressure, body temperature and visual acuity. Complementary evaluation was done by electrocardiogram, chest x-ray and laboratory tests (hemogram, renal function, liver function and thyroid function). All adverse events were graduated according to the Common Terminology Criteria for Adverse Events (CTCAEV). Efficacy was considered when the patients did not need further pleural procedure after pleurodesis and quality of life analysis was determined by questionnaire. RESULTS: Sixty patients were enrolled, thirty in each group, 55 females and 5 males. Mean age was 55,9 ± 11,7. The mainly etiology of malignant pleural effusion was breast cancer, in 43 patients, followed by lung cancer and ovarian tumor. We found 47 serious adverse events, possibly related to iodopovidone pleurodesis that occurred in 34 patients on 30 days follow-up. Most frequent clinical adverse events of these were pain, eleven patients, hypertension, ten and empyema in one patients. Serious metabolic events founded were hyponatremia in eight patients, alkaline phosphatase, alanine aminotransferase and aspartate aminotransferase increased in ten, three and one patients respectively and hypokalemia in one patient. Success rate occurred in 96%. We didn\'t find change on quality of life after pleurodesis. We found no difference in patient\'s demographical data, occurrence of adverse events, efficacy and quality of life between groups. CONCLUSIONS: Observed common and serious adverse events related to iodopovidone pleurodesis were pain, hypertension, and some metabolic alterations. We found good efficacy for iodopovidone pleurodesis, but no significant change in patient\'s quality of life after procedure. This report does not suggest dose-dependent relation for the occurrence of adverse events

Abstract There are previous reports of an increasing incidence of children’s forearm fractures in the last few decades. Their surgical treatment is evolving. The present study was aimed at determining the incidence and background of these fractures and their treatment. It was also aimed to analyse the short- and long-term outcomes. A comprehensive population-based study (N=168) among 86,000 children in Oulu University Hospital District over a decade (2000–2009) was performed to analyse the incidence of middle-third forearm fractures. Further data (N=291) covering 1997–2009 was achieved in order to study monthly variation and backgrounds of all both-bone forearm fractures in the distal, middle or proximal thirds. An age- and sex-matched case-control study (N=94) at Vaasa Central Hospital District in 1995–1999 with approximately 11 years of follow-up was performed to evaluate long-term morbidity. The relationship between summer weather and outdoor fractures was based on daily weather readings of all summer days (N=1989) in 1997–2009. There was a 4.4-fold increase in middle-third shaft fractures in the last decade (2000–2009) and a 3.1-fold increase in all forearm shaft fractures (proximal, middle and distal) in 1997–2009. The increase in the middle-shaft fractures was still accelerating towards the end of the study period. Trampolining was increasing as a reason for the injuries. At the end of the study every third fracture was caused by a trampoline injury. The fractures caused by other recreational activities increased absolutely, but they were stable in relation to trampoline injuries. There was a clear monthly variation in fracture incidence. During the long study time, August was repeatedly the most usual month for the fractures. School terms and summer holidays did not explain the varying fracture risk. The incidence of the fractures was 50% higher in dry vs. rainy days in summer. Temperature and wind speed did not affect fracture risk. Not only were the number of children’s forearm shaft fractures increasing, but also their operative treatment in 1997–2009. The increase was mostly connected to elastic stable intramedullary nailing (ESIN), the incidence of which changed from 10% to 30% during the study period, compared with other types of treatment. Non-operative treatment showed poor short-term outcome in the form of worsening alignment and a relatively great need of re-operations. Operative treatment showed excellent primary results. In the long run, the outcome of non-operative treatment was excellent. / Tiivistelmä Lasten kyynärvarren diafyysimurtumat ovat lisääntyneet viimeisten vuosikymmenten aikana. Samalla niiden kirurginen hoito on muuttunut. Tämän tutkimuksen tavoitteena oli selvittää murtumien ilmaantuvuutta ja murtumien taustalla olevia tekijöitä sekä hoidon kehittymistä. Tavoitteena oli myös tutkia lyhyt- ja pitkäaikaisia hoitotuloksia. Ilmaantuvuuden määrittämiseksi kerättiin väestöpohjainen aineisto (N=168) kaikista niistä lapsista (&#60;16-v.), jotka ovat olleet hoidossa Oulun yliopistollisessa sairaalassa kyynärvarren keskialueen murtuman vuoksi 2000–2009. Taustatekijöiden selvittämiseksi aineisto laajennettiin koskemaan kaikkia kyynärvarren kahden luun murtumia (proksimaaliset, keskialueen ja distaaliset murtumat) 1997–2009 (N=291). Pitkäaikaistuloksia arvioitiin tapaus-verrokkitutkimuksella (N=94), jonka potilasaineiston muodostivat Vaasan keskussairaalassa vuosina 1995–1999 hoidetut lapsipotilaat. Ikä- ja sukupuolivakioidut vertailutapaukset poimittiin väestörekisteristä. Kesäsään ja ulkona tapahtuvien murtumien välisen yhteyden tutkimiseksi kerättiin säätila-aineisto kaikilta vuosien 1997–2009 kesäpäiviltä (N=1989). Lasten kyynärvarren keskidiafyysin murtumat lisääntyivät 4,4-kertaisesti vuosikymmenessä (2000–2009) ja kaikki diafyysimurtumat lisääntyivät 3,1-kertaisesti (1997–2009). Keskidiafyysimurtumien ilmaantuvuus kasvoi kiihtyvästi. Trampoliini aiheutti yksinään joka kolmannen murtuman, ja trampoliinimurtumien ilmaantuvuus kasvoi tutkimusaikana. Muut tapaturmatyypit pysyivät vakioisina. Murtumien ilmaantuvuus vaihteli kuukausittain, mutta 13 vuoden seurantajaksolla ne olivat selvästi yleisimpiä elokuussa. Koululaisten kesäloma ei vaikuttanut murtumariskiin. Murtumat olivat 50 % yleisempiä kuivalla säällä kuin sadesäällä. Lämpötila tai tuulennopeus eivät vaikuttaneet murtumien ilmaantuvuuteen. Lasten kyynärvarsimurtumien operatiivinen hoito lisääntyi. Joustavien ydinnaulojen käyttö kasvoi 10 %:sta 30 %:iin suhteessa muihin hoitomuotoihin. Kajoavan hoidon lyhytaikaiset tulokset olivat erinomaiset. Kajoamattoman hoidon tulokset olivat heikot, ja hoitoon liittyi paljon asennon huonontumista ja myöhempää leikkaustarvetta, erityisesti asennon korjaamista. Pitkän ajan seurannassa kajoamattoman hoidon tulokset olivat kuitenkin erinomaiset. / Sammanfattning Barns underarmsfrakturer har ökat under de senaste årtiondena och deras behandling är under förändring. Syftet med den här forskningen var att undersöka underarmsfrakturer: förekommande, bakgrund och behandling. Meningen var också att bedöma resultat av olika frakturbehandlingar på kort och lång sikt. Totalt 168 barn undersöktes. De behandlades på Uleåborgs universitetssjukhus åren 2000–2009 p.g.a. en underarmsfraktur i mellersta tredjedelen av skaft. Därtill inkluderades 291 barn med en underarmsfraktur i hela skaftet åren 1997–2009. En fall-kontroll–undersökning innehöll 47 barn med en underarmsfraktur i Vasa centralsjukhus åren 1996–1999 samt en köns- och ålders standardiserad kontroll grupp med 47 medlemmar (N=47). Relationen mellan sommarväderlek och frakturer som skedde utomhus analyserades på basis av uppgifter om väderleken på alla sommardagarna åren 1997–2009 (N=1989). Frakturer i den mellersta underarmen ökade 4,4-faldigt och accelererande på ett årtionde (2000–2009) och alla skaftfrakturer 3,1-faldigt (1997–2009). Trampolinen tillfogade var tredje av dessa frakturer och således ökade trampolinens betydelse. Jämfört med trampolinen höll sig andra bakgrundsfaktorer stadiga. Det fanns en klar variation i förekommande av frakturer mellan månaderna. Mest förekom frakturer i augusti. Skolperioden eller sommarlovet påverkade inte risken för frakturer. Uppehållsväder ökade risken 1,5-faldigt jämfört med regniga dagar. Temperaturen eller vinden hade ingen effekt på frakturer. Operativa kirurgiska behandlingar ökade i stället för ej-operativa behandlingar åren 1997–2009. Ökningen berodde mest på tilltagande bruk av flexibla märgspikar, vilket ökade från 10 % till 30 % jämfört med andra behandlingsmetoder. Ej-operativ vård visade gott om komplikationer under den korta uppföljningen. Operativ vård var framgångsrik på kort sikt. Däremot visade ej-operativ behandling utmärkta resultat efter den långa uppföljningen.

<p>Veno-arterijski gradijent ugljen-dioksida (Pv-aCO2) se smatra pokazateljem adekvatnosti microcirculatornog venskog protoka. U stanjima usporenog protoka dolazi do povećavanja Pv-aCO2 zbog fenomena zadržavanja CO2. Vrednost Pv-aCO2 predložena je kao dodatni cilj rane usmerene terapije kod pacijenata sa septičnim &scaron;okom. Cilj rada bilo je utvrditi postojanje korelacije promene Pv-aCO2 s promenom SOFA (&ldquo;Sequential Organ Failure Assessment&rdquo;) skora (delta SOFA) nakon primene rane ciljane terapije, kao i korelacije vrednosti različitih pokazatelja krvnog protoka unutar prvih 12 sati od početka lečenja pacijenata sa sepsom. Sekundarni cilj bilo je utvrditi postojanje korelacije Pv-aCO2 6 sati nakon početka rane ciljane terapije (T6) s dužinom boravka u intenzivnoj jedinici i ishodom lečenja. Prospektivnim, neintervencijskim ispitivanjem obuhvaćeno je 150 pacijenata sa sepsom ili septičnim &scaron;okom. Merenja serumskog laktata, saturacije kiseonikom me&scaron;ane venske krvi (ScvO2) i Pv-aCO2 vr&scaron;ena su na početku rane ciljane terapije (T0), posle 6 i 12 sati (T6, T12). Pv-aCO2 se računao kao razlika između parcijalnog pritiska ugljen dioksida arterijske i me&scaron;ane venske krvi. Vrednost SOFA skora određivana je u vremenu T0 i nakon 48 časova (T48). Pacijenti su za potrebe analize podeljeni u dve grupe na osnovu promene SOFA skora [(1) pacijenti kod kojih je do&scaron;lo do smanjenja SOFA skora (delta SOFA &lt; 0); (2) pacijenti kod kojih je smanjenje SOFA skora izostalo (delta SOFA &ge; 0)] i na osnovu vrednosti Pv-aCO2 u vremenu T6 [(1) pacijenti sa visokim Pv-aCO2 (&ge; 0.8 kPa); (2) pacijenti sa normalnim Pv-aCO2 (&lt; 0.8 kPa)]. Između dve grupe pacijenata, sa normalnim i visokim Pv-aCO2, statistički značajne razlike uočene su samo u odnosu na najvi&scaron;u vrednost respiratorne komponente SOFA skora (p=0.01). Uočena je statistički značajna korelacija između vrednosti Pv-aCO2 i laktata u vremenu T6 (r=0.2), Pv-aCO2 i ScvO2 u vremenu T0 (r=-0.4) i T12 (r=-0.24) kao i laktata i ScvO2 u vremenu T0 (r=-0.26) i T12 (r=-0.18). Analizom ponavljanih merenja nije utvrđena statistički značajna korelacija između promene vrednosti Pv-aCO2 unutar prvih 6 sati s promenom SOFA skora unutar prvih 48 sati nakon početka rane ciljane terapije (p=0.12). Utvrđeno je da su vrednosti Pv-aCO2 u vremenu T6 bile lo&scaron; prediktor smrtnog ishoda. Nisu utvrđene statistički značajne razlike u dužini boravka u intenzivnoj jedinici i ishodu lečenja u zavisnosti od vrednosti Pv-aCO2.</p> / <p>Central venous-arterial CO2 difference (Pv-aCO2) reflects adequacy of microcirculatory venous flow. Widening of Pv-aCO2 due to CO2-stagnant phenomenon is described in the low flow states. Pv-aCO2 was proposed as an additional resuscitation target for patients with septic shock.The aim of this study was to examine correlation between changes in Pv-aCO2 and SOFA score as well as different blood flow indices (lactate, mixed venous oxygen saturation) 12 hours after onset of resuscitation in patients with sepsis or septic shock. Secondary aim was to evaluate association of delta CO2 6 hours after onset of resuscitation and patient outcomes (length of stay in the ICU, mortality). Prospective observational study included 150 patients with sepsis. Simultaneous measurements of lactate, mixed venous oxygen saturation (ScvO2) and delta PCO2 were performed at onset of resuscitation (T0) and after 6 hours (T6). Delta PCO2 was calculated as a difference between arterial PCO2 and PCO2 from mixed venous blood. Organ dysfunction was evaluated with the Sequential Organ Failure Assessment (SOFA) score at T0 and after 48 hours (T48). Mortality was assessed after 28 days. For data analysis purposes two groups were created based on delta SOFA [(1) patients with SOFA score decrease (delta SOFA &lt;0); (2) patients without SOFA score decrease (delta SOFA &ge; 0)] and based on Pv-aCO2 [(1) patients with high Pv-aCO2 (&ge;0.8 kPa); (2) patients with normal Pv-aCO2 (&lt;0.8 kPa). Patients with high and normal Pv-aCO2 differed only with respect to highest respiratory SOFA score (p=0.01) Change in Pv-aCO2 between T0 and T6 was not in correlation with change in SOFA score between T0 and T48 (p=0.12). Moderate statistically significant correlation was found between Pv-aCO2 and lactate at T6 (r=0.2), and moderate inverse correlation between Pv-aCO2 and ScvO2 at T0 (r=-0.4) and T12 (r=-0.25) and ScvO2 and lactate at T0 (r=-0.27) and T12 (r=-0.18). Pv-aCO2 at T6 was not associated with 28-day mortality and length of stay in the ICU.</p>

O vírus da hepatite C (HCV) é uma importante causa de doença hepática crônica e de complicações associadas, tais como cirrose e hepatocarcinoma (HCC). Fatores virais e do hospedeiro são conhecidos preditores da terapia antiviral. Fatores do hospedeiro preditores da resposta viral sustentada (RVS) foram descobertos por estudos de associação genômica ampla (GWAS), correspondendo a polimorfismos de nucleotídeo único (SNPs) nos genes IFNL3 e IFNL4 (rs8099917, rs12979860 e rs368234815). O objetivo do presente trabalho foi verificar as frequências genotípicas dos SNPs rs8099917, rs12979860 e rs368234815 e avaliar a associação entre estes SNPs e a evolução clínica e a resposta ao tratamento da infecção pelo HCV tendo em conta a ancestralidade genética da população estudada. Neste estudo, foi observada a associação dos três polimorfismos tanto com o desfecho clínico quanto com a resposta ao tratamento com interferon peguilado (PEG-IFN) e ribavirina (RBV). Os polimorfismos rs12979860 e rs368234815 foram associados com aumento da sensibilidade (respectivamente 97,7%, IC 95% 87,2-100, e 93,3%, IC 95% 81,3-98,3) e com um maior valor preditivo de uma resposta positiva ao tratamento. Na análise multivariada ajustada por sexo, idade e ancestralidade genética, o haplótipo G/T/?G foi relacionado com a não-resposta ao tratamento (OR = 21,09, IC 95% 5,33-83,51; p < 0,001) e com uma chance maior de desenvolver infecção crônica (OR = 5,46, IC 95% 2,06-14,46; p=0,001), quando comparado com haplótipo T/C/TT. Estes resultados podem ajudar a ajustar políticas de tratamento para a infecção por HCV em populações com tais características genéticas, assim como nos permitem conhecer o perfil genético da nossa população em relação a esses polimorfismos / Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and associated complications such as liver cirrhosis and hepatocellular carcinoma (HCC). Viral and host factors are known to be predictors for anti-viral therapy. Host factors predictors of sustained viral response (SVR) were discovered by Genome-Wide Association Studies (GWAS), including single nucleotide polymorphisms (SNPs) near or on genes IFNL3 and IFNL4 (rs8099917, rs12979860 and rs368234815). The aim of the present work was verify the genotype frequencies of SNPs rs8099917, rs12979860 and rs368234815, and evaluate the association between these SNPs and HCV infection outcome taking into account the genetic ancestry of the population. In this study, there was an association of the three polymorphisms with both clinical outcome and response to treatment with pegylated interferon (PEG-IFN) and ribavirin (RBV). The polymorphisms rs12979860 and rs368234815 showed increased sensitivity (97.7%, 95% CI 87.2-100, and 93.3%, 95% CI 81.3-98.3 respectively) and greater predictive value of a positive response to treatment. In multivariable analysis adjusted by gender, age and genetic ancestry, the haplotype G/T/?G was related to non-response to treatment (OR = 21.09, 95% CI 5.33-83.51; p < 0.001) and to a higher chance to develop chronic infection (OR = 5.46, 95% CI 2.06-14.46; p=0.001) when compared to haplotype T/C/TT. These findings may help to adjust our treatment policies for HCV infection in populations with such genetic characteristics, as well as allowing us to get to know the genetic profile of our population for these polymorphisms

Introdução: A terapia de ressincronização cardíaca (TRC) é um tratamento recomendado pelas principais diretrizes mundiais para pacientes com insuficiência cardíaca congestiva (ICC), disfunção ventricular esquerda (FE <= 35%), com tratamento otimizado e distúrbio da condução intraventricular, principalmente pelo ramo esquerdo. Entretanto, 30%-40% dos pacientes selecionados não respondem ao tratamento. As razões desse insucesso não são completamente conhecidas. Existe, portanto, necessidade de desenvolvimento de índices multifatoriais para melhor selecionar e acompanhar a evolução e o prognóstico destes pacientes. Objetivo: Elaborar modelos preditores de risco de óbito cardíaco ou transplante (Tx), em diferentes fases da TRC. Métodos e Casuística: Estudo observacional, prospectivo e analítico, com inclusão de 116 pacientes, entre 01/2008 a 03/2013, sendo 69,8% do sexo masculino, com CF III (68,1%) e IV ambulatorial (31,9%), com BRE em 71,55% e com idade de 64,89 ± 11,18 anos e fração de ejeção (FE) de 29%. Avaliações foram feitas no período pré-implante (tempo 1), 6-12 meses (tempo 2) e 18-24 meses (tempo 3) e correlacionadas com a mortalidade cardíaca/Tx no final do seguimento. Foram estudadas variáveis clínicas, eletrocardiográficas e ecocardiográficas e realizadas análises de regressão de Cox e regressão logística, com a construção da curva ROC. As curvas de sobrevidas foram realizadas pelo método de Kaplan-Meier e comparadas pelo log-rank. Modelos e escores foram elaborados pelas pontuações do \"hazard ratio\", utilizado como variável independente no modelo de regressão logística. Resultados: Ocorreram 29 (25%) óbitos/Tx durante o seguimento de 34,09 ± 17,9 meses. A mortalidade cardíaca/Tx foi de 16,3 % (19 pacientes). Seis pacientes foram transplantados durante o tempo do estudo. No período préimplante (tempo 1), a presença de disfunção de ventrículo direito (VD), FE < 25% e o uso de altas doses de diuréticos (dois ou mais comprimidos de furosemida) mostraram-se com valor independente, com aumento de risco de óbito cardíaco/Tx de 3,9; 4,8 e 5,9 vezes, respectivamente. No tempo 2 (1° ano), as variáveis disfunção de VD, altas doses de diuréticos e internações por ICC foram as variáveis significativas, com aumento de risco 3,5; 5,3 e 12,5 respectivamente. No tempo 3 (2° ano), as variáveis disfunção de VD e classe funcional III/IV foram significativas no modelo multivariado de Cox, com aumento de risco de 12,1 e 7,7. As acurácias dos modelos foram 84,6%; 93% e 90,5%, respectivamente. Conclusão: Os modelos preditores de óbito cardíaco desenvolvidos a partir de variáveis clínicas e ecocardiográficas, obtidas em diferentes fases da TRC, mostraram boa acurácia e podem ajudar na seleção, seguimento, definição de resposta e aconselhamento destes pacientes / Introduction: Cardiac resynchronization therapy (CRT) is indicated for patients with congestive heart failure (CHF), ejection fraction (EF) <= 35%, and bundle branch block. However, 30%-40% do not respond to CRT. Therefore, there is a need to develop multifactorial indexes to better select and follow these patients. Objective: This work aims to develop predictive models for the risk of cardiac death or transplantation (Tx) at different stages of CRT. Methods: We performed a prospective observational study of 116 patients, 69.8% males, functional class (FC) III (68.1%) and IV (31.9%), LBBB in 71.55%, age 64.89 ± 11.18 years. We studied clinical, electrocardiographic, and echocardiographic variables and performed Cox and logistic regression with ROC and Kaplan- Meier curves. Results: The cardiac mortality was 16.3% (19 patients) in the 34.09 ± 17.9 follow-up months. Pre-implantation, the right ventricular dysfunction (RVD), EF <25%, and the use of high doses of diuretics (HDD) increased risk of cardiac death or Tx of 3.9, 4.8, and 5.9 fold, respectively, and in the first year, the variables RVD, HDD, and hospitalizations for CHF increased risk of death of 3.5, 5.3, and 12.5, respectively. In the 2nd year, the variables RVD and FC III / IV (NYHA) were significant in the multivariate Cox model. The accuracies of the models were 84.6%, 93%, and 90.5%, respectively. Conclusions: Cardiac death predictive models were developed in different stages of CRT, and were based on the analysis of simple clinical and echocardiographic variables. The models showed good accuracy and can help in the selection and follow-up of these patients

<p>Reumatoidni artritis (RA) je hronično inflamatorno oboljenje zglobova koji nastaje usled poremećaja u regulaciji imunskih mehanizama. TNF-alfa jedan je od ključnih medijatora inflamacije u RA, a koji preko složenih mehanizama podstiče aktivnost osteoklasta koji dovodi do poremećaja u procesu ko&scaron;tanog remodelovanja u pravcu povećane ko&scaron;tane resorpcije koji se klinički može pratiti određivanjem nivoa markera ko&scaron;tane resorpcije i ko&scaron;tanog formiranja u urinu i serumu. Primenom TNF inhibitora započeo je novi koncept lečenja RA. Cilj rada: Utvrditi razliku mineralne ko&scaron;tane gustine (BMDg/cm2) i vrednosti ko&scaron;tanih biohemijskih markera-prokolagen tip 1N-terminalni propeptid (P1NP) i beta-crosslapsa pre uvođenja terapije, i nakon godinu dana sprovedene terapije TNF inhibitorima. Metode: Studija je sprovedena u Specijalnoj bolnici za reumatske bolesti Novi Sad jednim delom kao retrospektivno, a drugim delom prospektivno istraživanje, koje je obuhvatilo 50 bolesnica sa dijagnozom reumatoidnog artritisa kod kojih je postojala indikacija za uvođenje lekova iz grupe TNF inhibitora. Da bi u&scaron;le u studiju bolesnice su morale da ispune određene uključne/isključne kriterijume koji su bili vezani za dužinu trajanja RA i menopauze, način lečenja RA, stepen o&scaron;tećenja zglobova i prisutnost drugih oboljenja sa reperkusijom na ko&scaron;tano tkivo. Pored reumatolo&scaron;kog i fizikalnog pregleda određivani su faktori rizika za osteoporozu i prelome. Na početku i na kraju godinu dana po uvođenju terapije TNF inhibitora rađena je osteodenzitometrija na aparatu tipa &bdquo;Lunar&ldquo; merena na lumbalnoj kičmi i kuku kao i određivanje biohemijskih markera u serumu prokolagen tip 1 N-terminalni propeptid (P1NP) i betacrosslapsa ECLIA metodom. Rezultati: Prosečna starost bolesnica bila je 51,5 godina koje su u 84%, bolovale od RA do 5 godina kod kojih je u najvećem procentu dužina trajanja menopauze bila do dve godine, a u svojoj terapiji pored metotreksata su imale uključen TNF inhibitor, Etanercept 34%, Adalimubam 46%, Golimubam 9% i 2% Infliksimab.Pre uvođenja biolo&scaron;ke terapije najveći broj bolesnica 80% imalo je osteopeniju, 14% normalan nalaz, dok je osteoporoza zabeležena kod 6% bolesnica. Na kraju jednogodi&scaron;nje primene TNF inhibitora 18% bolesnica je imalo normalan osteodenzitometrijski nalaz, 78 % osteopeniji, a 4% osteoporozu. Ova promena je statistički značajna ( p=0,000). Nakon jednogodi&scaron;nje primene TNF inhibitora nije do&scaron;lo do smanjenja vrednosti BMD (g/cm&sup2;) merenog na lumbalnom delu kičme i kuka. Beleži se statističko značajno povećanje vrednosti T- skora (SD) merenog na lumbalnom delu kičme i vratu butne kosti. Vrednost ko&scaron;tanih biohemijskih markera P1NP i beta crosslapsa značajno su povećani nakon jednogodi&scaron;nje primene TNF inhibitora, pri čemu se beleži veće povećanje biohemijskog markera ko&scaron;tane sinteze, P1NP. Zaključak: Savremeni pristup lečenja reumatoidnog artritisa podrazumeva primenu biolo&scaron;kih lekova kao &scaron;to su TNF inhibitori koji značajno suzbijaju inflamaciju i dovode do smanjenja odnosa RANKL/OPG sistema, čime se inhibira dejstvo osteoklasta i sprečava gubitak mineralne ko&scaron;tane gustine. Primena TNF inhibitora nakon godinu dana sprečila je pad vrednosti BMD (g/cm&sup2;), povećana je vrednost T- skora (SD) i vrednosti ko&scaron;tanih biohemijskih markera, posebno markera ko&scaron;tane sinteze. Uprkos velikom broju studija vezanih za dejstvo TNF inhibitora na kost, za sada nema dovoljan broj istraživanja o njegovom uticaju na sprečavanju osteoporoze i preloma kostiju i nivou vrednosti ko&scaron;tanih biohemijskih markera posebno u dužem periodu praćenja, &scaron;to će biti verovatno predmet daljih istraživanja.</p> / <p>Rheumatoid arthritis (RA) is a chronic inflammatory joint disease resulting from compromised regulation of immune mechanisms. TNF-alpha is one of the key inflammation mediators in RA that, through complex mechanisms stimulates osteoclast activity, thereby modifying the bone remodeling process in the direction of increased bone resorption that can be clinically monitored by determining the level of bone resorption and bone formation markers in urine and serum. Use of TNF has initiated a new concept in RA treatment. Aims: To determine the differences in bone mineral density (BMD, g/cm2) and values of biochemical markers in bone procollagentype 1 N-terminal propeptide(P1NP) and betacrosslaps before and after yearlong TNF inhibitor therapy. Methods: The study was conducted at the Special Hospital for Rheumatic Diseases Novi Sad partly as retrospective and partly as prospective research, which involved 50 female patients diagnosed with rheumatoid arthritis in whom introduction of medications from the TNF inhibitor group was indicated. To be included in the study, patients had to meet certain inclusion/exclusion criteria related to RA and menopause duration, RA treatment, degree of joint impairment, and presence of comorbidities with repercussions for bone tissues. In addition to rheumatological and physical examinations, risk factors for osteoporosis and fractures were determined. At the beginning and one year after commencing TNF inhibitor therapy, osteodensitometry was performed using &ldquo;Lunar&rdquo; apparatus, taking measurements on lumbar spine and hip, and serum levels of biochemical markers procollagentype 1 Nterminal propeptide(P1NP) and beta-crosslaps were determined via ECLIA method. Results: Mean patient age was 51.5 years, 84% of whom suffered from RA for up to 5 years, and in the greatest percentage experienced menopause for two years, receiving therapy that in addition to methotrexate included a TNF inhibitor, Etanercept 34%, Adalimumab 46%, Golimumab 9%, and 2% Infliximab. Prior to commencing biological therapy, majority of patients 80% suffered from osteopenia, 14% had normal findings, and osteoporosis was recorded in 6% of patients. At the end of yearlong TNF inhibitor therapy, 18% of patients had normal osteodensitometry findings, 78% had osteopenia and 4% osteoporosis. This change was statistically significant (p = 0.000). As a result of yearlong TNF inhibitor therapy no reduction occurred in BMD (g/cm&sup2;) values in lumbar spine and hip. Statistically significantly higher T scores (SD) pertaining to lumbar spine and femur were measured. Values of biochemical markers P1NP and beta-crosslaps significantly improved after yearlong TNF inhibitor therapy, whereby a greater increase was recorded in the biochemical bone synthesis marker, P1NP. Conclusion: Advanced rheumatoid arthritis treatment involves the use of biological compounds such as TNF inhibitors that significantly suppress inflammation and reduce the RANKL/OPG ratio, thereby inhibiting osteoclast activity and preventing bone mineral loss. TNF inhibitor therapy after one year prevented reduction in the BMD (g/cm&sup2;) levels, while increasing the T score (SD) and bone biochemical marker values, bone synthesis marker in particular. Despite a large number of studies related to the TNF inhibitor effect on bone, there is presently not enough research on its influence on osteoporosis and bone fracture prevention and bone biochemical marker levels, especially over longer periods, which will likely be the topic of further research.</p>

<p>Brahiterapija visokim brzinama doze (HDR&ndash;BT) predstavlja efikasan modalitet zračenja kod pacijenata sa lokalizovanim karcinomom prostate (CaP) svih rizika. Za razliku od transkutane radioterapije i brahiterapije niskim brzinama doze (LDR&ndash;BT), kod ove grupe pacijenata u intersticijalnoj HDR&ndash;BT jo&scaron; uvek nisu jednoznačno definisane ukupne doze zračenja, način frakcionisanja kod pacijenata sa lokalizovanim CaP različitih rizika. U periodu od 2009&ndash;2018.god. HDR&ndash;BT kao jedinim načinom lečenja (monoterapija) u Op&scaron;toj bolnici Medicinski sistem Beograd, lečeno je 35 pacijenata (6 (17,1%) pacijenata niskog rizika, 21 (60%) pacijent srednjeg rizika i 8 (22,9%) pacijenata visokog rizika) sa lokalizovanim CaP različitih rizika od relapsa i progresije bolesti. Grupe pacijenata sa srednjim i visokim rizikom spojene su u jednu grupu (grupa sa vi&scaron;im rizikom). Tehnika sprovođenja HDR&ndash;BT, osim u pojedinačnim specifičnim detaljima, bila je slična kao i kod LDR&ndash;BT. Aplikacija igala, segmentacija, delineacija i planiranje HDR&ndash;BT vr&scaron;eno je kori&scaron;će&scaron;em transrektalnog ultrazvuka (TRUS) i izocetričnog radioskopskog C&ndash;luka, a zračenje je sprovedeno na uređaju Microselectron HDR sa zatvorenim radioaktivnim izvorom 192Ir početne aktivnosti 370 GBq. Aplikovane terapijske doze (TD), u opsegu od 30&ndash;57 Gy frakcionisane su u 3&ndash;4 nezavisne frakcije sa razmakom od 2&ndash;3 nedelje između frakcija, a individualizovane su prema nivou rizika, stanju organa u riziku (OAR) i kvalitetu aplikacije (indeksu prekrivanja CTV sa planiranom terapijskom dozom (CI100%) i mogućno&scaron;ću za&scaron;tite OAR). Uspe&scaron;nost terapije ocenjivana je postignutom biohemijskom kontrolom (BFS &ndash; biochemical&ndash;free&ndash;survival), prema ASTRO i Phoenix kriterijumima, kao i ukupnim preživljavanjem u periodu od 5 godina (2&ndash;9 godina) posle sprovedene terapije. U niskorizičnoj grupi pacijenata lečenih HDR&ndash;BT, BFS je postignuta kod svih pacijenata kao i ukupno preživljavanje. U grupi pacijenata sa vi&scaron;im rizikom BFS je postignuta kod 95,8% lečenih pacijenata, a ukupno 5&ndash;to godi&scaron;nje preživljavanje je 96,4%. BFS u ovom istraživanju se pokazala statistički značajnije bolja nego ona koju su prikazali drugi autori. Na osnovu rizika, nivoa PSA, TD i indeksa pokrivenosti CTV sa TD, izvr&scaron;eno je modelovanje terapijskih parametara kori&scaron;ćenjem MANN (multilauyer artificial neural network). Određena optimalna doza zračenja (TD) u HDR&ndash;BT lokalizovanog CaP niskog rizika je 40,7 Gy za CI100% = 1,01. Kod vi&scaron;ih rizika TD = 50,9 Gy za CI100% = 1,6. TD se frakcioni&scaron;e u 4 nezavisne frakcije sa razmakom od 2&ndash;3 nedelje. Ovakav izbor parametara HDR&ndash;BT (TD, CI100%, i način frakcionisanja), uz individualizaciju i kontrolu u toku svake aplikacije, obezbedio bi prihvatljiv nivo kasnih postiradijacionih komplikacija gradusa G1&ndash;G3 na uretri (&lt; 17% ukupnog broja lečenih pacijenata), uz minimimalne komplikacije na rektumu (pretežno G1&ndash;G2) i zanemarljive komplikacije na mokraćnoj be&scaron;ici.</p> / <p>High&ndash;dose rate brachytherapy (HDR&ndash;BT) is an effective therapy modality for patients with localized prostate cancer (CaP) of all risks. In contrast to an external beam radiotherapy and low&ndash;dose rate brachytherapy (LDR&ndash;BT), in these patients, the interstitial HDR&ndash;BT, the total radiation dose and fractionation is not unambiguously defined. Between 2009&ndash;2018 35 patients with localized CaP (6 (17.1%) low&ndash;risk patients, 21 (60%) patients medium&ndash;risk and 8 (22.9%) high&ndash;risk) were treated with HDR&ndash;BT, as the only treatment (monotherapy) in the General Hospital Medical System Belgrade. The group of patients with medium&ndash;risk and high&ndash;risk were merged into a single group (group with a higher&ndash;risk). Technique implementation of HDR&ndash;BT was similar as in the LDR&ndash;BT. Application of needles, segmentation, delineation, and planning of HDR&ndash;BT was performed with transrectal ultrasound (TRUS) and izocentrically mounted radioscopic C&ndash;arm. Irradiation was done on the Microselectron&ndash;HDR brachytherapy unit with a sealed radioactive source 192Ir (370 GBq). The dose (TD), in the range of 30&ndash;57 Gy was given fractionated in independent fractions (3&ndash;4) with a pause of 2&ndash;3 weeks between fractions. TD was individualized according to the risk, the conditions of organs at risk (OAR) and quality of the application (coverage index CI100%), as well as, the ability to protect OAR. Treatment result was evaluated by the achieved biochemical control (BFS &ndash; biochemical&ndash;free&ndash;survival) according to ASTRO and/or Phoenix criteria, as well as an overall survival in the period of 5 years (2&ndash;9 years) after the completion of the treatment. In the low&ndash;risk group, BFS has been achieved in all patients and overall survival rate is 100%. In the group of patients with higher risk BFS was achieved in 95.8% of treated patients, and 5&ndash;year survival rate was 96.4%. BFS in this study was proved to be statistically significantly better than showed by other authors. On the basis of the risk, the level of PSA, TD and CI100%, modeling was performed using the MANN (multilayer artificial neural network). The determined optimal dose TD for localized CaP of low risk is 40.7 Gy for CI100% = 1.0. At higher risk TD = 50.9 Gy for CI100% = 1.6. TD was given in 4 independent fractions with the interval of 2&ndash;3 weeks between each fraction. These HDR&ndash;BT parameters (TD, CI100%, and the fractionation scheme) with the individualization and control during each application would provide an acceptable level of late complications grade G1&ndash;G3 to the urethra (in less than 17% of treated patients), with minimum complications on the rectum (predominantly grade G1&ndash;G2) and insignificant complications rate on the urinary bladder.</p>

<p>Urođeni rascep sa naborom u prednjoj srednjoj liniji vrata (UR-N PSLV) je retka anomalija sa oko 100-150 bolesnika opisanih u literaturi. Tipičan rascep se sastoji od atrofične, ružičaste kože u obliku žleba, kožne prominencije na gornjem kraju i potkožnog sinusa na donjem kraju tzv. rascepa. Ispod ovih elemenata nalazi se potkožna vezivno-mi&scaron;ićna traka koja izaziva nabor na vratu. Izolovani nabor vrata, kao jedan od tipova rascepa, ima samo potkožnu traku i podbradnu kožnu izraslinu. U radu analiziramo seriju od 11 bolesnika sa UR-N PSLV operisanih u periodu od 12 godina (jul 1998. - jun 2010.). Rezultati lečenja sagledani su u pogledu preciznosti postavljanja dijagnoze (diferencijalna dijagnoza anomalija i oboljenja PSLV) i analize posleoperativnih funkcionalnih i estetskih karakteristika (vrednost cervikomentalnog ugla-CMU, veličina ekstenzije glave i vrata-EGV i karakteristike ožiljka). Rezultati operativnog lečenja rascepa primenom multiple &bdquo;Z&rdquo; plastike sa 4-10 kožnih režnjeva poređeni su sa Sistrunkovom operacijom kod bolesnika sa cistom tiroglosnog duktusa-TGDC (ukupno 128 bolesnika u seriji). S obzirom na veliki broj bolesnika sa različitim izgledom anomalije učinjena je podela UR-N PSLV na tipove (I-IV) i podtipove. Rascep se po embriopatogenezi, izgledu i patohistolo&scaron;kim (PH) karakteristikama jasno razlikuje od TGDC. Deskriptivnom embriologijom rascep se defini&scaron;e kao poremećaj u spajanju prednjih krajeva II (nekad i I) ždrelnih lukova. Kompresija srca u razvoju i odloženo ispravljanje vrata imaju značajnu ulogu. Kožna izraslina je rabdomiomatozni mezenhimalni hamartom kod svih na&scaron;ih bolesnika. Kaudalni sinus po PH izgledu ukazuje na bronhogeno poreklo. Operacijom rascepa vrata ne postiže se normalan CMU i potpuna EGV. Operacijom TGDC vi&scaron;e se menja CMU nego EGV, ali su vrednosti bliže kontrolnoj grupi nego kod dece sa rascepom. Ožiljci, posebno kosi delovi &bdquo;Z&rdquo; plastike, posle operacije UR-N su lo&scaron;ije&nbsp; ocenjeni nego posle operacije TGDC (parametrijski testovi pokazuju manju razliku). Na estetiku i funkcionalnost vrata i glave posle operacije rascepa veoma mnogo utiču hipoplazija donje vilice i deficit mekih struktura prednje strane vrata. Nova operativna tehnika (poprečna eliptična ekscizija i incizija u dva nivoa ili <em>step incision</em>, sa dodatnom &bdquo;Z&rdquo; plastikom na platizmi) primenjena kod dva bolesnika (pri kraju analize rezultata u studiji) daje nadu u dobijanje boljih posleoperativnih rezultata.</p> / <p>Congenital midline cervical cleft and web (CMCC-W) is a rare anomaly with about 100-150 cases described in the literature. The typical CMCC consists of midline groove of atrophic, erythematous skin with a skin protuberance cranially, and a subcutaneous blind sinus tract on the lower end of so-called cleft. Subcutaneous fibro-muscular band is located underneath, causing the web. Isolated CMCW, as one of the cleft types, includes only subcutaneous band and submental skin prominence. We analyzed a series of 11 patients with CMCC-W during the 12-year period (July 1998-June 2010). Treatment outcomes were evaluated according to precisely established diagnosis (differential diagnosis of anomalies and diseases of midline neck) and analysis of postoperative functional and aesthetic features (value of cervico-mental angle (CMA), head and neck extension (HNE) and characteristics of the scar). The results of the surgical treatment using multiple Z-plasty technique with 4-10 skin flaps were compared with Sistrunk procedure in patients with thyroglossal duct cyst (TGDC) (total of 128 patients in the series). Since a great number of patients had different forms of anomaly, the cases were divided into types (I-IV) and subtypes. Regarding embryo pathogenesis, appearance and histopathology, there was a clear difference between CMCC and TGDC. A cleft is defined, due to descriptive embryology, as a failure of the second (sometimes and first) pharyngeal arches to fuse in the midline. Compression of the heart and postponed extension of the neck played an important role during development period. Skin prominence was a rhabdomyomatous mesenchymal hamartoma in all our patients. Histopathology of the caudal sinus indicated the bronchogenic origin. The normal CMA and complete HNE were not achieved by the operation of CMCC-W. TGDC operation effects more CMA than HNE, but the values are closer to control group than in children having a cleft. Scars, especially oblique parts of Z plasty, after the operation CMCC-W were worse than after TGDC (parametric tests showed lesser difference). Hypoplasia of the mandible and vertical soft-tissue deficit of the anterior neck have a great impact on aesthetics and functionality of the head and neck after cleft surgery. New operative technique (two level transverse elliptical excision and incision or step incision &ndash; with the additional Z-plasty of platysma) was applied in two patients (at the end of the analysis of the results in the study) gives a new hope regarding better postoperative results.</p>